Search Results - "Subbiah, Vivek"

Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?

Authors: Desai, Aakash Subbiah, Vivek Roy-Chowdhuri, Sinchita et al.

Source: Cancers. Nov2024, Vol. 16 Issue 22, p3753. 8p.

Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment.

Authors: Subbiah, Vivek Oliver, Thomas K. Palma, Jim et al.

Source: JCO Precision Oncology. 4/3/2026, Vol. 10, p1-7. 7p.

Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid Carcinoma.

Authors: Hamidi, Sarah Subbiah, Vivek Cabanillas, Maria E. et al.

Source: JCO Precision Oncology. 2/20/2026, Vol. 10, p1-7. 7p.

Molecular-Guided Precision Oncology in Cancer of Unknown Primary: A State-of-the-Art Perspective.

Authors: Subbiah, Vivek Rassy, Elie Greco, Frank A.

Source: Journal of Personalized Medicine. Feb2026, Vol. 16 Issue 2, p80. 15p.

Reconsidering Asparaginase in Leukemia Therapy.

Authors: Frost, Maria Subbiah, Vivek Cuglievan, Branko et al.

Source: Acta Haematologica. Mar2026, p1-3. 3p.

Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.

Authors: Murray, Suzanne Subbiah, Vivek Sherman, Steven I. et al.

Source: Thyroid Research. 8/14/2023, Vol. 16 Issue 1, p1-12. 12p.

DiscovHER PAN-206: Phase 2 tumour-agnostic study of Zanidatamab in patients with previously treated human epidermal growth factor receptor 2 (HER2)-overexpressing solid tumours.

Authors: Subbiah, Vivek Makker, Vicky Oh, Do-Youn et al.

Source: Gynecologic Oncology. May2026:Supplement, Vol. 208, pS144-S145. 2p.

Redefining pancreatic cancer management with tumor-agnostic precision medicine.

Authors: Reddy, Neha K Subbiah, Vivek

Source: Carcinogenesis. Nov2024, Vol. 45 Issue 11, p836-844. 9p.

Optimizing Tomorrow's Drug Development with Project Optimus: Precision Dosing IS Precision Oncology.

Authors: Subbiah, Vivek¹ (AUTHOR) Vivek.subbiah@scri.com

Source: Annals of Oncology. Oct2024, Vol. 35 Issue 10, p836-839. 4p.

Precision oncology across the ages: Impact on children, adolescents, and young adults.

Authors: Subbiah, Vivek Kurzrock, Razelle

Source: Cancer Cell. Sep2024, Vol. 42 Issue 9, p1473-1479. 7p.

The case for tumour-agnostic reimbursement of dual immunotherapy.

Authors: Subbiah, Vivek Kurzrock, Razelle

Source: European Journal of Cancer. Jun2026, Vol. 241, pN.PAG-N.PAG. 1p.

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.

Authors: Subbiah, Vivek Dumbrava, Ecaterina Ileana Jiang, Yunfang et al.

Source: Experimental Hematology & Oncology. 4/20/2020, Vol. 9 Issue 1, p1-8. 8p.

Revolutionizing cancer drug development: Harnessing the potential of basket trials.

Authors: Subbiah, Vivek Burris, Howard A. Kurzrock, Razelle

Source: Cancer (0008543X). Jan2024, Vol. 130 Issue 2, p186-200. 15p.

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.

Authors: Subbiah, Vivek Hu, Mimi I. Mansfield, Aaron S. et al.

Source: Thyroid. Jan2024, Vol. 34 Issue 1, p26-40. 15p.

Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer.

Authors: Lin, Edwin Lo, Ying-Chun Subbiah, Vivek et al.

Source: Experimental Hematology & Oncology. 7/11/2025, Vol. 14 Issue 1, p1-5. 5p.

Rare disease research powered by empowered patients: solving the zebra puzzle through social media.

Authors: Morgan, Gilberto Subbiah, Vivek

Source: Cancer (0008543X). Jul2023, Vol. 129 Issue 14, p2128-2131. 4p.

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.

Authors: Subbiah, Vivek Chuang, Hubert H. Kairemo, Kalevi et al.

Source: Diagnostics (2075-4418). Mar2017, Vol. 7 Issue 1, p10. 17p.

Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy.

Authors: Desai, Aakash Subbiah, Vivek

Source: Cancer (0008543X). Jan2023, Vol. 129 Issue 1, p11-14. 4p.

Bridging tumour classification and treatment.

Authors: Subbiah, Vivek Westphalen, Benedikt Curigliano, Guiseppe et al.

Source: Lancet Oncology. Jul2025, Vol. 26 Issue 7, pe343-e344. 2p.

TRKing sarcomas for precision medicine: Seek, and ye shall find!

Authors: Moyers, Justin T. Subbiah, Vivek

Source: Cancer (0008543X). Dec2023, Vol. 129 Issue 23, p3694-3696. 3p.